Our country will participate in a global scale medicine clinical trial

Our country will participate in a global scale medicine clinical trial
Our country will participate in a global scale medicine clinical trial
It is reported ' Reporter Li TianShu) Recently, in the intersection of conference and " cardiovascular disease study hot forum outside the Oxford - mound ", heart of China, Have, the scholar reveals, our country will participate in global large-scale many centre medicine clinical trials, strengthen his spit of fland medicine and control cardiovascularly to have illness coming on on the function of the risk. Transship albumens (CETP) through inhibiting cholesterol ester Raise high density lipoprotein, reduce low the intersection of density and lipoprotein, in use the intersection of he and spit of fland make every effort, make cardiovascular to have illness coming on new hope that the risk further drops at the the intersection of medicine and foundation. But because first the intersection of CETP and the intersection of inhibitor and Torcetrapib cause energies run affairs increase of one and stop ahead of time. Medical science later was analyzed and found, this inhibitor produced the side effect of aldosterone level increasing, electrolytic disorder, cause energies run affairs a increased root of the trouble. At present, lower lipoprotein intensity Anacetrapib in inhibitor in most strong CETP, clinical 3 study, reveal inhibitor this can reduce 40% low the intersection of density and lipoprotein, raise 140% of the high density lipoprotein, but not influenced the aldosterone level, electrolyte, have not found either that there is an obvious side effect. The hospital Oxford international medical research center director new professor Jiang Li of China of cardiovascular disease says outside the mound of the Chinese Academy of Medical Sciences, CETP inhibitor Anacetrapib studies by the design of university of Oxford and organizes the implementation, will select the medical organization and launch large-scale many centre clinical trials in the world soon, this test will be selected 30,000 and endangered the disease patient of cardiovascular vessel high, and China regards as the important participant, be selected 9400 patients, the whole plan will be expected to last 4 years. Jiang Li's new introduction, the international medical research center of Oxford of China is responsible for implementing in the area of China, has already basically confirmed more than 80 families of cooperation unit at present, register nearly ten thousand patients, it is estimated that starts this research formally at the end of this year.


|